Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial launched in the US Market

Gland Pharma Limited (BSE: 543245 / NSE: GLAND), a generic injectable focused pharmaceutical company, earlier this week, through its partner has launched Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US Market. It is the bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade® for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A., Inc.

Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.

Velcade has a market size of USD 1,172 million for the twelve months ending March 2022, according to IQVIA.

Gland Pharma's partner has received the ANDA approval for the product from U.S. Food & Drug Administration (US FDA). Gland Pharma is manufacturing and supplying this product to its partner for the US market.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 3205.20 as compared to the previous close of Rs. 3203.50. The total number of shares traded during the day was 6293 in over 1605 trades.

The stock hit an intraday high of Rs. 3236.05 and intraday low of 3195.05. The net turnover during the day was Rs. 20234142.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 Bortezomib Injection USMarket ProductLaunch